The Weekly Five | 5–11 October

Five studies worth your time this week, spanning randomized evidence, long-term toxicity, salvage treatment, surveillance and particle-therapy QA.

1. NRG-BR002 finds no survival benefit from metastasis-directed ablation

Adding SBRT or surgery to systemic therapy did not improve progression-free or overall survival in randomized patients with oligometastatic breast cancer.

Read post

2. Left atrial and ventricular doses predict cardiac events after breast RT

After 16.5 years, left atrial dose was associated with major cardiac events, while left ventricular dose tracked with coronary disease.

Read post

3. BNCT shows high response but limited durability in head and neck cancer

In recurrent or unresectable head and neck cancer, BNCT achieved 80% response but only 42% two-year local control, with 2.1% fatal toxicity.

Read post

4. Regular surveillance is associated with better survival after nasopharyngeal cancer

Among 8,798 patients, regular surveillance, particularly distant-site imaging, was associated with better survival, although the retrospective design limits causal conclusions.

Read post

5. ESTRO-EPTN introduces new guidance for particle-therapy quality assurance

New recommendations support staged adoption of independent dose calculation and log-file QA, with phantom measurements reduced only after local validation.

Read post

That's the week. See you next Sunday.

Browse more research Suggest a correction